Crossmark

Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China

Crossref DOI link: https://doi.org/10.1007/s40261-018-0702-9

Published Online: 2018-09-07

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Pingyu

Ma, Aixia

Liu, Qiang
License Information

Text and Data Mining valid from 2018-09-07
More Information

Article History

First Online: 7 September 2018

Compliance with Ethical Standards

:

: No funding has been received for the conduct of this study.

: All authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below